These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23000597)

  • 1. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
    D'Haens G; Feagan B; Colombel JF; Sandborn WJ; Reinisch W; Rutgeerts P; Carbonnel F; Mary JY; Danese S; Fedorak RN; Hanauer S; Lémann M;
    Gastroenterology; 2012 Dec; 143(6):1461-9. PubMed ID: 23000597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment of inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.
    Travis S; Feagan BG; Rutgeerts P; van Deventer S
    J Crohns Colitis; 2012 Feb; 6 Suppl 2():S250-9. PubMed ID: 22463932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine blockade in inflammatory bowel diseases.
    Perrier C; Rutgeerts P
    Immunotherapy; 2011 Nov; 3(11):1341-52. PubMed ID: 22053885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging biological treatments in inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Rutgeerts P; Vermeire S; Van Assche G
    Gut; 2007 Apr; 56(4):453-5. PubMed ID: 17369375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease.
    de Silva PS; Nguyen DD; Sauk J; Korzenik J; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2012 Sep; 36(5):459-66. PubMed ID: 22784296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?
    Marteau P; Sokol H; Dray X; Seksik P
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S228-34. PubMed ID: 20117346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate in inflammatory bowel disease.
    Feagan BG; Alfadhli A
    Gastroenterol Clin North Am; 2004 Jun; 33(2):407-20, xi. PubMed ID: 15177546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.